Table 15.

The Monoclonal Antibodies of PD-1 and PD-L1.

Target	Agent	Sponsor	Class	Clinical Testing Phase
PD-1	Nivolumab	Bristol-Myers Squibb	Human IgG4	FDA-approved for treatment of refractory unresectable melanoma , for metastatic NSCLC and advanced renal cell carcinoma
	Pembrolizumab	Merck	Humanized IgG4	FDA-approved for treatment of refractory unresectable melanoma and for metastatic NSCLC that expresses PD-1
	CT-011	CureTech	Humanized IgG1k	Phase 1–2
	AMP-224	Amplimmune	PD-L2 IgG2a fusion protein	Phase 1
	MEDI0680 (AMP-514)	Amplimmune	PD-L2 fusion protein	Phase 1–2
	REGN2810	Regeneron	Human IgG4	Phase 1
	PDR001	Novartis	Information not available	Phase 1–2
	JS001-PD-1	ShangHai JunShi
	SHR-1210	ShangHai HengRui
	BMS-936559	Bristol-Myers Squibb	Human IgG4	Phase 1–2
PD-L1	MEDI4736	MedImmune/AstraZeneca	Humanized IgG1k	Phase 1–3
	MPDL3280A	Roche	Human IgG1k	FDA-approved for treatment of urothelial carcinoma
	MSB0010718C	Merck Serono	Human IgG1	Phase 1–3